Addiction & Substance Use

Cannabis use during adolescence can profoundly impact brain development.

Social media is here to stay, and its use must be a consideration in the treatment of psychiatric conditions, particularly substance use disorder and alcohol use disorder.

Learn more about cannabis use and social media addiction in this month's Special Report!

What influence do legislation and social-based decisions have on individual mental health, like in the case of drag performers?

The FDA has issued a complete response letter to Orexo for OX124, a high-dose naloxone nasal spray for opioid overdose reversal.

What is new in research on alcohol use disorder?

To expertly utilize polypharmacy, it is imperative that clinicians stay abreast of new literature, check for drug-drug interactions, and be aware of emerging trends in drug use.

Inhalant use disorder is characterized by the intentional inhalation of volatile substances for their psychoactive effects. Learn more about how to help manage this disorder.

An expert discusses this comorbidity, plus the effects of semaglutide and other GLP-1 agonists on this patient population.

The FDA has authorized the marketing of 4 menthol-flavored e-cigarette products in the United States through the premarket tobacco product application pathway.

Cannabis withdrawal syndrome impacts approximately half of those who use it regularly. How can you help patients cease cannabis use?

With cannabis legalization increasing in the United States, so too are the issues surrounding cannabis access, usage, and use disorders. State by state, take a peek at some of the issues and updates surrounding cannabis.

Here are highlights from the week in Psychiatric Times.

We're highlighting issues in addiction in our special Digital Supplement! Learn more here.

The study aims to collect data to optimize the design of the treatment’s upcoming phase 3 clinical trial.

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

An analysis presented at the ASCP Annual Meeting explored the safety and tolerability of the treatment for alcohol and tobacco use disorders.

Write to us now for a chance to be featured in our upcoming Special Report on Addiction.

Here are highlights from the week in Psychiatric Times.

Here’s how an integrated psychosocial and pharmacologic approach can enhance SUD treatment.

Here are highlights from the last day of this year’s APA Annual Meeting.

The Psychiatric Times Substance Use Section Editor reflects on the theme of the 2024 Annual Meeting, plus what he is most excited about in psychiatry.

Here are highlights from the third day of this year’s APA Annual Meeting.

This 2024 APA Annual Meeting poster documented the abuse potential of benzodiazepines and tapering challenges.

Here are highlights from the second day of this year’s APA Annual Meeting.